Skip to main content
All lobbying filings

PRIME THERAPEUTICS

PRIME THERAPEUTICS filed a Q1 report for PRIME THERAPEUTICS on April 20, 2026.

Lobbying for PRIME THERAPEUTICS

All filings by PRIME THERAPEUTICS · Everything PRIME THERAPEUTICS has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$120,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Minnesota

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Health Issues

H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices S. 2355 Patients Deserve Price Tags Act provisions related to drug price transparency and patient transparency tools S. 3822, Break Up Big Medicine Act provisions related to insurer/PBM ownership or pharmacies S. 1954/HR 5526 The Biosimilar Red Tape Elimination Act -provisions related to interchangeability of biosimilars Department of Labors Notice of Proposed Rulemaking, Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure (RIN 1210-AB37).

Medicare/Medicaid

H.R. 8143 Ensuring Access to Lower Cost Medicines for Seniors Act of 2026 provisions related to formulary placement of certain drugs. H.R. 7148 (now Public Law 119-75) The Consolidated Appropriations Act provisions regulating pharmacy benefit manager practices H.R. 1227, Alternatives to PAIN Act requirements related to formulary Tierring and prior authorization in Medicare Part D for non-opioid pain medications.

 Bills named in this filing 7
  • H.R. 7148
    Consolidated Appropriations Act, 2026
  • S. 2355
    Patients Deserve Price Tags Act
  • S. 3822
    Break Up Big Medicine Act
  • S. 1954
    Biosimilar Red Tape Elimination Act
  • H.R. 5526
    Biosimilar Red Tape Elimination Act
  • H.R. 8143
    Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.
  • H.R. 1227
    Alternatives to PAIN Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem